Télécharger le supplément (250 p.) - KCE

More documents

Recommendations

Info

142 Médecine à l'acte / médecine au forfait - ANNEXES KCE Reports 85 S Parameter Estimate Standard Error t Value Pr > |t| age*aidsoc 85-+ ans 2 0.0000000 B . . . im*inv 1 1 -48.4825338 B 12.3965435 -3.91
KCE Reports 85 S Médecine à l'acte : médecine au forfait - ANNEXES 143 Parameter Estimate Standard Error t Value Pr > |t| prep*VPO 2 1 0.0000000 B . . . prep*VPO 2 2 0.0000000 B . . . prep*aidsoc 1 1 14.7464353 B 68.4456696 0.22 0.8294 prep*aidsoc 1 2 0.0000000 B . . . prep*aidsoc 2 1 0.0000000 B . . . prep*aidsoc 2 2 0.0000000 B . . . VPO*chom3 1 1 28.9527824 B 42.1248756 0.69 0.4919 VPO*chom3 1 2 0.0000000 B . . . VPO*chom3 2 1 0.0000000 B . . . VPO*chom3 2 2 0.0000000 B . . . VPO*aidsoc 1 1 -34.5760994 B 30.1056880 -1.15 0.2508 VPO*aidsoc 1 2 0.0000000 B . . . VPO*aidsoc 2 1 0.0000000 B . . . VPO*aidsoc 2 2 0.0000000 B . . . chom3*aidsoc 1 1 -28.8521386 B 17.7796992 -1.62 0.1047 chom3*aidsoc 1 2 0.0000000 B . . . chom3*aidsoc 2 1 0.0000000 B . . . chom3*aidsoc 2 2 0.0000000 B . . . The X'X matrix has been found to be singular, and a generalized inverse was used to solve the normal equations. Terms whose estimates are followed by the letter 'B' are not uniquely estimable. Essai 2 - en enlevant les intéractions non significatives Class Level Information Class Levels Values age 7 1-4 ans 25-39 ans 40-64 ans 5-24 ans 65-74 ans 75-84 ans 85-+ ans im 2 1 2 inv 2 1 2 PP0020 2 1 2 prep 2 1 2 VPO 2 1 2 chom3 2 1 2 aidsoc 2 1 2 Number of Observations Read 21778 Number of Observations Used 21778 Source DF Sum of Squares Mean Square F Value Pr > F Model 34 75306804.2 2214906.0 79.96 F age 6 50190860.22 8365143.37 302.00
Page 1 and 2:
Comparaison du coût et de la quali
Page 3 and 4:
Comparaison du coût et de la quali
Page 5 and 6:
KCE Reports 85 S Médecine à l’a
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96: KCE Reports 85 S Médecine à l’a
Page 113 and 114: KCE Reports 85 S Médecine à l'act
Page 145: KCE Reports 85 S Médecine à l'act
Page 197 and 198:
KCE Reports 85 S Médecine à l'act
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
This page is left intentionally bla
Page 247 and 248:
KCE reports 1. Efficacité et renta
Page 249:
74. Oxygénothérapie Hyperbare: Ra
show all

Télécharger le supplément (250 p.) - KCE

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?